Read by QxMD icon Read

Diabetes Care

Sadanori Okada, Takeshi Morimoto, Hisao Ogawa, Mio Sakuma, Chisa Matsumoto, Hirofumi Soejima, Masafumi Nakayama, Naofumi Doi, Hideaki Jinnouchi, Masako Waki, Izuru Masuda, Yoshihiko Saito
OBJECTIVE: This study analyzed the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes. RESEARCH DESIGN AND METHODS: This study was a posttrial follow-up of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial. Participants in the JPAD trial (2,536 Japanese patients with type 2 diabetes and without preexisting cardiovascular disease) were randomly allocated to receive aspirin (81 or 100 mg daily) or no aspirin...
June 16, 2018: Diabetes Care
Stephanie Brinkhues, Nicole H T M Dukers-Muijrers, Christian J P A Hoebe, Carla J H van der Kallen, Annemarie Koster, Ronald M A Henry, Coen D A Stehouwer, Paul H M Savelkoul, Nicolaas C Schaper, Miranda T Schram
OBJECTIVE: The relation between clinical complications and social network characteristics in type 2 diabetes mellitus (T2DM) has hardly been studied. Therefore, we examined the associations of social network characteristics with macro- and microvascular complications in T2DM and investigated whether these associations were independent of glycemic control, quality of life, and well-known cardiovascular risk factors. RESEARCH DESIGN AND METHODS: Participants with T2DM originated from the Maastricht Study, a population-based cohort study ( n = 797, mean age 62...
June 15, 2018: Diabetes Care
Sven Kohler, Stefan Kaspers, Afshin Salsali, Cordula Zeller, Hans J Woerle
OBJECTIVE: To assess the effect of empagliflozin on bone fractures and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study versus glimepiride. RESEARCH DESIGN AND METHODS: Pooled data were analyzed from patients who were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in phase I-III clinical trials. Data were also analyzed from the EMPA-REG H2H-SU trial in which patients received empagliflozin 25 mg or glimepiride as an add-on to metformin for 104 weeks with a 104-week extension...
June 15, 2018: Diabetes Care
David Beran, Irl B Hirsch, John S Yudkin
No abstract text is available yet for this article.
June 15, 2018: Diabetes Care
Bernard Zinman, Steven P Marso, Erik Christiansen, Salvatore Calanna, Søren Rasmussen, John B Buse
OBJECTIVE: In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) cardiovascular (CV) outcomes trial (NCT01179048), liraglutide significantly reduced the risk of CV events (by 13%) and hypoglycemia versus placebo. This post hoc analysis examines the associations between hypoglycemia and CV outcomes and death. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and high risk for CV disease ( n = 9,340) were randomized 1:1 to liraglutide or placebo, both in addition to standard treatment, and followed for 3...
June 14, 2018: Diabetes Care
Tina Costacou, Jamie Crandell, Anna R Kahkoska, Angela D Liese, Dana Dabelea, Jean M Lawrence, David J Pettitt, Kristi Reynolds, Elizabeth J Mayer-Davis, Amy K Mottl
OBJECTIVE: We assessed the association between diet quality and microalbuminuria in youth-onset type 1 diabetes using three indices: a modified Mediterranean diet score for children and adolescents (mKIDMED), the Dietary Approaches to Stop Hypertension (DASH), and the Healthy Eating Index-2010 (HEI). RESEARCH DESIGN AND METHODS: Youth and young adults from the SEARCH (Search for Diabetes in Youth) Nutrition Ancillary Study diagnosed with type 1 diabetes in 2002-2008, who had repeated dietary assessments at baseline and follow-up visits and urine albumin-to-creatinine ratio (UACR) measured at the outcome visit (2012-2015) ( n = 461), were selected for study...
June 14, 2018: Diabetes Care
Ilse C Schrieks, Anna Nozza, Barbara E Stähli, John B Buse, Robert R Henry, Klas Malmberg, Bruce Neal, Stephen J Nicholls, Lars Rydén, Linda Mellbin, Anders Svensson, Hans Wedel, Arlette Weichert, A Michael Lincoff, Jean-Claude Tardif, Diederick E Grobbee, Gregory G Schwartz
OBJECTIVE: In observational cohorts, adiponectin is inversely associated and free fatty acids (FFAs) are directly associated with incident coronary heart disease (CHD). Adiponectin tends to be reduced and FFAs elevated in type 2 diabetes. We investigated relationships of adiponectin and FFA and major adverse cardiovascular events (MACEs) and death in patients with acute coronary syndrome (ACS) and type 2 diabetes using data from the AleCardio trial, which compared the PPAR-α/γ agonist aleglitazar with placebo...
June 14, 2018: Diabetes Care
Christina V Mangurian, Dean Schillinger, John W Newcomer, Eric Vittinghoff, Susan M Essock, Zheng Zhu, Wendy T Dyer, Julie A Schmittdiel
No abstract text is available yet for this article.
June 13, 2018: Diabetes Care
Michael A Nauck, Thomas Jon Jensen, Carina Rosenkilde, Salvatore Calanna, John B Buse
OBJECTIVE: This study explored neoplasm risk with liraglutide versus placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) cohort. RESEARCH DESIGN AND METHODS: LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind, controlled trial. Participants aged ≥50 years with type 2 diabetes and high cardiovascular risk were assigned 1:1 to receive liraglutide (≤1.8 mg daily; n = 4,668) or placebo ( n = 4,672) in addition to standard care and monitored for 3...
June 13, 2018: Diabetes Care
David C Klonoff, Joan Lee Parkes, Boris P Kovatchev, David Kerr, Wendy C Bevier, Ronald L Brazg, Mark Christiansen, Timothy S Bailey, James H Nichols, Michael A Kohn
OBJECTIVE: Cleared blood glucose monitor systems (BGMs) for personal use may not always deliver levels of accuracy currently specified by international and U.S. regulatory bodies. This study's objective was to assess the accuracy of 18 such systems cleared by the U.S. Food and Drug Administration representing approximately 90% of commercially available systems used from 2013 to 2015. RESEARCH DESIGN AND METHODS: A total of 1,035 subjects were recruited to have a capillary blood glucose (BG) level measured on six different systems and a reference capillary sample prepared for plasma testing at a reference laboratory...
June 13, 2018: Diabetes Care
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill, Narendra Singh Choudhary, Ambrish Mithal
OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human liver fat are scarce. This study examined the effect of empagliflozin (an SGLT-2 inhibitor) on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) by using MRI-derived proton density fat fraction (MRI-PDFF). RESEARCH DESIGN AND METHODS: Fifty patients with type 2 diabetes and NAFLD were randomly assigned to either the empagliflozin group (standard treatment for type 2 diabetes plus empagliflozin 10 mg daily) or the control group (standard treatment without empagliflozin) for 20 weeks...
June 12, 2018: Diabetes Care
Robert Ritzel, Stewart B Harris, Helen Baron, Hermes Florez, Ronan Roussel, Melanie Espinasse, Isabel Muehlen-Bartmer, Nianxian Zhang, Monica Bertolini, Claire Brulle-Wohlhueter, Medha Munshi, Geremia B Bolli
OBJECTIVE: SENIOR compared the efficacy and safety of insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in older people (≥65 years old) with type 2 diabetes. RESEARCH DESIGN AND METHODS: SENIOR was an open-label, two-arm, parallel-group, multicenter phase 3b trial designed to enroll ∼20% of participants aged ≥75 years. Participants were randomized 1:1 to Gla-300 or Gla-100, titrated to a fasting self-monitored plasma glucose of 5...
June 12, 2018: Diabetes Care
Alexander Turchin, Olukayode Sosina, Huabing Zhang, Maria Shubina, Sonali P Desai, Donald C Simonson, Marcia A Testa
OBJECTIVE: To investigate the association between ambulatory medication reconciliation and health care utilization in patients with diabetes. RESEARCH DESIGN AND METHODS: In this retrospective cohort analysis, we studied adults taking at least one diabetes medication treated in primary care practices affiliated with two academic medical centers between 2000 and 2014. We assessed the relationship between the fraction of outpatient diabetes medications reconciled over a 6-month period and the composite primary outcome of combined frequency of emergency department (ED) visits and hospitalizations over the subsequent 6 months...
June 11, 2018: Diabetes Care
Beverley M Shields, Timothy J McDonald, Richard Oram, Anita Hill, Michelle Hudson, Pia Leete, Ewan R Pearson, Sarah J Richardson, Noel G Morgan, Andrew T Hattersley
OBJECTIVE: The decline in C-peptide in the 5 years after diagnosis of type 1 diabetes has been well studied, but little is known about the longer-term trajectory. We aimed to examine the association between log-transformed C-peptide levels and the duration of diabetes up to 40 years after diagnosis. RESEARCH DESIGN AND METHODS: We assessed the pattern of association between urinary C-peptide/creatinine ratio (UCPCR) and duration of diabetes in cross-sectional data from 1,549 individuals with type 1 diabetes using nonlinear regression approaches...
June 7, 2018: Diabetes Care
Gail Musen, Liane J Tinsley, Katrina A Marcinkowski, David Pober, Jennifer K Sun, Maya Khatri, Richie Huynh, Annie Lu, George L King, Hillary A Keenan
OBJECTIVE: Patients with type 1 diabetes now live long enough to experience cognitive decline. During middle age, they show mild cognitive deficits, but it is unknown whether severity increases with aging or whether cognitive profiles are similar to those of age-matched peers with and without diabetes. RESEARCH DESIGN AND METHODS: We tested and compared cognition in 82 individuals with 50 or more years of type 1 diabetes (Medalists), 31 age-matched individuals with type 2 diabetes, and 30 age-matched control subjects without diabetes...
June 5, 2018: Diabetes Care
Juan F Navarro-González, María Dolores Sánchez-Niño, Javier Donate-Correa, Ernesto Martín-Núñez, Carla Ferri, Nayra Pérez-Delgado, José Luis Górriz, Alberto Martínez-Castelao, Alberto Ortiz, Carmen Mora-Fernández
OBJECTIVE: The effect of pentoxifylline on Klotho levels in patients with type 2 diabetes with chronic kidney disease (CKD) was assessed in a post hoc analysis of the PREDIAN trial. RESEARCH DESIGN AND METHODS: Circulating and urinary tumor necrosis factor-α (TNF-α) and Klotho were measured before and after 1 year of pentoxifylline. The effect on Klotho expression was assessed in cultured renal tubular cells. RESULTS: Pentoxifylline administration resulted in decreased serum and urinary TNF-α, whereas serum and urinary Klotho increased significantly...
June 4, 2018: Diabetes Care
Bethany Warren, Casey M Rebholz, Yingying Sang, Alexandra K Lee, Josef Coresh, Elizabeth Selvin, Morgan E Grams
OBJECTIVE: Long-term kidney disease trajectories in persons with and without diabetes in a general population are largely uncharacterized. RESEARCH DESIGN AND METHODS: We classified 15,517 participants in the community-based Atherosclerosis Risk in Communities (ARIC) study by diabetes status at baseline (1987-1989; no diabetes, undiagnosed diabetes, and diagnosed diabetes). We used linear mixed models with random intercepts and slopes to quantify estimated glomerular filtration rate (eGFR) trajectories at four visits over 26 years...
June 1, 2018: Diabetes Care
Adam Hulman, Daniel R Witte, Dorte Vistisen, Beverley Balkau, Jacqueline M Dekker, Christian Herder, Mensud Hatunic, Thomas Konrad, Kristine Færch, Melania Manco
OBJECTIVE: Glucose measurements during an oral glucose tolerance test (OGTT) are useful in predicting diabetes and its complications. However, knowledge of the pathophysiology underlying differences in glucose curve shapes is sparse. We examined the pathophysiological characteristics that create different glucose curve patterns and studied their stability and reproducibility over 3 years of follow-up. RESEARCH DESIGN AND METHODS: We analyzed data from participants without diabetes from the observational cohort from the European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease study; participants had a five-time point OGTT at baseline ( n = 1,443) and after 3 years ( n = 1,045)...
May 31, 2018: Diabetes Care
Petr Jarolim, William B White, Christopher P Cannon, Qi Gao, David A Morrow
OBJECTIVE: Patients with type 2 diabetes are at increased risk of developing heart failure (HF). Enhanced recognition of patients at risk for HF would help guide therapeutic decisions. RESEARCH DESIGN AND METHODS: We investigated the prognostic implications of changes in N-terminal B-type natriuretic peptide (NT-proBNP) concentration in patients with type 2 diabetes and ischemic heart disease who were enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, a phase 3b trial of alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor...
May 30, 2018: Diabetes Care
Panu K Luukkonen, Sanja Sädevirta, You Zhou, Brandon Kayser, Ashfaq Ali, Linda Ahonen, Susanna Lallukka, Véronique Pelloux, Melania Gaggini, Ching Jian, Antti Hakkarainen, Nina Lundbom, Helena Gylling, Anne Salonen, Matej Orešič, Tuulia Hyötyläinen, Marju Orho-Melander, Aila Rissanen, Amalia Gastaldelli, Karine Clément, Leanne Hodson, Hannele Yki-Järvinen
OBJECTIVE: Nonalcoholic fatty liver disease (i.e., increased intrahepatic triglyceride [IHTG] content), predisposes to type 2 diabetes and cardiovascular disease. Adipose tissue lipolysis and hepatic de novo lipogenesis (DNL) are the main pathways contributing to IHTG. We hypothesized that dietary macronutrient composition influences the pathways, mediators, and magnitude of weight gain-induced changes in IHTG. RESEARCH DESIGN AND METHODS: We overfed 38 overweight subjects (age 48 ± 2, BMI 31 ± 1 kg/m2 , liver fat 4...
May 29, 2018: Diabetes Care
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"